Research insight
Editorial from
Carolina Santos
PhD Candidate in Economics at Nova SBE | Research Assistant at Nova SBE Health Management & Economics Knowledge Center
November 16, 2022
3. Good health and well-being

3. Good health and well-being

Ensuring access to quality health and promoting well-being for all, at all ages

Towards greater digitization in clinical trials?

Nova SBE Notes column at Netfarma contributes to the reflection in the health area by the members of the research center Nova SBE Health Economics and Management Knowledge Center. Carolina Santos, a PhD student, reflects upon the digitalization of clinical trials.

Clinical trials are used to ensure the efficacy and safety of new drugs and study new uses of drugs already available on the market. The clinical trials phase represents, on average, about 57.1% of the costs of developing new drugs. It is estimated that these costs have been increasing in recent decades due, among other reasons, to the type of drugs under study and increased regulatory compliance scrutiny [1,2]. Furthermore, the current pandemic has imposed additional challenges to the conduct of clinical trials already underway and to the start of new studies. In addition, the rigid social distancing rules and the fact that clinical trial participants are generally part of populations more vulnerable to COVID-19 caused many of these trials to be temporarily interrupted [3,4].

To mitigate the disruptions caused by the pandemic and allow the continuation (or the start) of clinical trials related to coronavirus or rare diseases and serious diseases, without adequate treatment alternatives, the European Commission (EC) issued guidelines that include some flexibility in the trials. However, it does not compromise the safety of the participants nor the quality of the studies. For clinical trials in progress, for example, the possibility of in-person visits to patients being replaced by telephone or video call follow-up was created. Similarly, test quality monitoring activities, traditionally done on-site, can be carried out remotely. However, the EC clarifies that this relaxation is temporary and will cease once the pandemic has passed. Additionally, the European Union Regulation (No. 536/2014) on clinical trials of medicinal products for human use - which repeals Directive 2001/20/EC regarding the simplification and harmonization of clinical trials in the EU - does not deal with issues related to the digitization of clinical studies. Based on these guidelines and regulations, we could deduce that the future of (partially) remote clinical trials in the EU would be compromised.

The recent guideline of the European Medicines Agency (EMA) on the use of computer systems and electronic data in clinical trials, which is in public consultation from June 18th to December 17th, 2021, shows, however, that there is an apparent effort to modernize the clinical trials paradigm in the EU. In this document, the EMA provides guidelines that should be followed to ensure the quality of data collected in the trials and to ensure the privacy, safety, and well-being of study participants. Electronic informed consent and data collection through wearable devices are some procedures that can revolutionize clinical trials and which are mentioned in the guideline.

The benefits of digitization in clinical trials are vast. As an illustration, the digital recruitment of trial participants increases the ability to reach populations traditionally underrepresented in studies, contributing to greater robustness of the results [5,6]. In turn, if they are adequately tested for the purpose, wearable devices offer the opportunity to remotely aggregate a large amount of data that would not be collected in the occasional face-to-face follow-up visits. In theory, these data provide a better understanding of the heterogeneity of responses to the treatments under study, increase the efficiency of clinical trials and reduce costs [7].

However, it should be noted that despite all the optimism placed on digitizing and conducting remote clinical trials, more evidence is still needed to understand its actual impact on trial costs and efficiency [7]. On the other hand, something that will undoubtedly help to reduce costs and encourage the conduct of international clinical trials in the EU is the harmonization provided for in the European Union Regulation (No. 536/2014), and the need to submit a single application for authorization for one trial - instead of multiple similar applications in different EU countries. It is hoped that, with this simplification, new drugs will reach those who need them more quickly. However, it remains to be seen how the potential reduction in the costs of clinical trials, and therefore the cost of developing new drugs, will affect drug prices in the EU.

(The Nova SBE Notes column contributes to the reflection in the health area by the members of the research center Nova SBE Health Economics and Management Knowledge Center. These are opinion articles under the sole responsibility of the authors.)

Carolina Santos
PhD Candidate in Economics at Nova SBE | Research Assistant at Nova SBE Health Management & Economics Knowledge Center

Keep reading

A new perspective on the Nova SBE Faculty & Staff Football Team: Fostering Well-being and Unity

In the bustling halls of Nova School of Business and Economics, where minds converge to shape the future of business and society, a lesser-known but vibrant community exists: the Nova SBE Faculty & Staff Football Team. Beyond the classroom walls and office cubicles, this team embodies camaraderie, passion, and a commitment to good health and well-being. Delve here into their story, dissecting it through a fresh lens, and uncovering practical insights that extend beyond theoretical musings.

3D printing of your pills

We all know what a pharmacy is: a place where we can obtain chemical products, which we call pharmaceuticals. Not long ago, these products were manufactured at the pharmacy. With the proper scientific advances and the development of modern manufacturing processes, the pharmacy evolved into a place that mostly makes available such chemical products and helps people by counseling them. Pedro Pita Barros enlightened us on this topic.

Rethinking public health spending sustainability

Keeping a growing healthcare system sustainable in developed economies might mean a raise in taxes or cost reducing actions in other sectors. How should a society and its governmental bodies reflect on its expenditure balance and priorities?

EuHEA 2020 Seminar Series

The EuHEA seminar series brings together health economists all across its member associations and beyond, to discuss cutting-edge research


Peak performance: Kilimanjaro leadership quest

In September 2023, Nova School of Business and Economics (Nova SBE) made history as 16 faculty and staff members embarked on an extraordinary journey — the Kilimanjaro Leadership Quest. This ambitious project saw the team conquer Africa's highest peak, Mount Kilimanjaro, imparting invaluable leadership, teamwork, and sustainability lessons.

Subscribe our weekly newsletter

By subscribing to the Nova SBE Role to Play newsletter, you can stay up-to-date on the latest articles posted on the website.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

We all have a role to play

We are on a mission to be a community dedicated to the development of talent and knowledge that impacts the world.

With just ten years to go, an ambitious global effort is underway to deliver the 2030 promise. We want to take a stand and we are calling on our community to showcase how they are contributing to the 17 Sustainable Development Goals, whilst influencing more and more people to unravel their role to play.

Here, you will find four different ways your ideas can flourish, dialogue can be enhanced, and action can take place. You can choose one or all four, and Nova SBE will be there to support you all the way and guarantee tangible change.

We all have a role to play, and this is your way in.